Non-cystic fibrosis bronchiectasis (NCFB) is a chronic, progressive respiratory disorder characterized by irreversibly and abnormally dilated airways, persistent cough, excessive sputum production and recurrent pulmonary infections. The changes in the bronchial walls may be due to chronic inflammation secondary to recurrent or chronic infections in the lung, but often the exact cause is not identified.1 Symptoms vary from intermittent episodes of respiratory infections with excessive mucus production to chronic symptoms with persistent daily expectoration of purulent sputum. Non-cystic fibrosis bronchiectasis is associated with comorbidities such as anxiety, depression, fatigue, and has a significant impact on quality of life.
This report contains market size and forecasts of Non-Cystic Fibrosis Bronchiectasis in Global, including the following market information:
Global Non-Cystic Fibrosis Bronchiectasis Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Non-Cystic Fibrosis Bronchiectasis market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Oral Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Non-Cystic Fibrosis Bronchiectasis include Aradigm Corporation, Zambon, Novartis Pharmaceuticals and Insmed Incorporated, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Non-Cystic Fibrosis Bronchiectasis companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Cystic Fibrosis Bronchiectasis Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Non-Cystic Fibrosis Bronchiectasis Market Segment Percentages, by Type, 2021 (%)
Oral
Intravenous
Global Non-Cystic Fibrosis Bronchiectasis Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Non-Cystic Fibrosis Bronchiectasis Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Others
Global Non-Cystic Fibrosis Bronchiectasis Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Non-Cystic Fibrosis Bronchiectasis Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Cystic Fibrosis Bronchiectasis revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Non-Cystic Fibrosis Bronchiectasis revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Aradigm Corporation
Zambon
Novartis Pharmaceuticals
Insmed Incorporated